Despite the clear loss of BTK activity in samples taken 1 month following commencement of therapy, we detected significant increases in SYK, LYN, JNK2, PKACα, PKN1, and TBK1 representation within kinome profiles of sIgM-stimulated CLL cells. This evidence concerns the gene MAPK9 and B-cell chronic lymphocytic leukemia.